newsfilter
← Latest News
Business Wire·

Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

First participants dosed in clinical trial of second-generation gingipain inhibitor differentiated by novel compound properties and anticipated once daily administration Clinical advancement of pipeline delivers on commitment to bring innovation to